Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 9,325 citations
https://doi.org/10.1056/nejmoa1507643
J
Jérôme Fayette
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
385
Papers
25.8K
Citations
49
h-index
143
i10-index
Jérôme Fayette is an academic researcher from Université Claude Bernard Lyon 1. The author has contributed to research in topics: Head and Neck Cancer Studies & Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations. The author has an h-index of 49, co-authored 328 publications.
ORCID: 0000-0002-8126-7019Papers by this author
worksAngiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases
2007 · Annals of Oncology · 393 citations
https://doi.org/10.1093/annonc/mdm381
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
2020 · Annals of Oncology · 360 citations
https://doi.org/10.1016/j.annonc.2020.04.001
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
2018 · European Journal of Cancer · 262 citations
https://doi.org/10.1016/j.ejca.2018.11.015
Critical Role of IL-12 in Dendritic Cell-Induced Differentiation of Naive B Lymphocytes,
1998 · The Journal of Immunology · 210 citations
https://doi.org/10.4049/jimmunol.161.5.2223
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
2014 · Annals of Oncology · 181 citations
https://doi.org/10.1093/annonc/mdu216
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat